Story of the Week (DR):Anthropic’s founders’ 80% giving pledge could be worth nearly $80 billion MMAnthropic’s Founders Pledged to Donate Most of Their Stock. Their IPO Tells Another Story.“In addition, our co-founders have each pledged to dedicate 80% of their personal equity in Anthropic to philanthropic causes. These commitments are voluntary, revocable expressions of each co-founder’s philanthropic intent and do not constitute legally binding obligations.”Americans Are Officially More Scared of AI Than a Loved One Getting CancerAnthropic IPO warns its AI could blackmail people, become sentient, end humanityAnthropic IPO (See Matt quiz)A24’s 2026 meta-documentary You Can See Everything, directed by Nathan Fielder and Lance Oppenheimcrossed $50M domestically faster than any non-concert documentary since Fahrenheit 9/11 and March of the Penguins.Billy Evans’ ‘Theranos 2.0’ startup has patents, investors, and a missing CTO—but no productZero Medical Experts on Theranos board: mostly included former U.S. officials and military leaders recruited by George SchultzTheranos was structured with dual-class stock giving Holmes shares with 100 votes each.A separate Board of Counselors was established after reputation damage from press reports and because of the board’s lack of medical and scientific expertise. It had zero fiduciary authority, no power to demand audited financial statements, and no authority to fire the CEO. Holmes leveraged their resumes on corporate letterheads for credibility while locking them out of corporate oversight.Elizabeth Holmes (2003–2018): Theranos founder/CEO/chairAs part of her 2018 SEC civil fraud settlement, Holmes was formally barred from serving as an officer or director of any public company for 10 years (2028)Channing Robertson (early years; exact dates unclear): Stanford chemical-engineering professor, Holmes’s mentor and Theranos’s first board member.Avie Tevanian (2006–2007): Apple’s former chief software technology officer and a Theranos director early on; he later said he raised concerns about the company’s progress and finances.Dolby Laboratories (2009-2021)George Shultz (2011–2016; Board Counselor until 2017): Former U.S. secretary of stateCharles Schwab; Gilead Sciences (Director Emeritus until 2019); Bechtel (private)Henry Kissinger (2011–2016): Former U.S. secretary of state and national security adviserHollinger International; ContiGroupWilliam Perry (2011–2016; Board Counselor until 2017): Former U.S. secretary of defenseFabrinet; CylinkSam Nunn (2011–2016; Board Counselor until 2017): Former U.S. senator and Senate Armed Services Committee chairmanThe Coca-Cola Company; General Electric; Dell; Chevron; Hess Corporation.Bill Frist (2011–2016; Board Counselor until 2017): Former U.S. senator, Senate majority leader and heart-transplant surgeonTeladoc Health; Select Medical Holdings; AECOM; AccoladeGary Roughead (2011–2016; Board Counselor until 2017): Retired U.S. Navy admiral and former chief of naval operationsNorthrop Grumman (2012-present)Richard Kovacevich (2011–2016): Former CEO/chair Wells FargoWells Fargo; Cisco Systems; TargetRiley Bechtel (2011–2016): Former CEO/chair of engineering and construction firm BechtelBechtel (private)Jim Mattis (2013–2017): Retired Marine Corps generalGeneral Dynamics (rejoined board in 2019)David Boies (2016): Prominent trial lawyer and chair of law firm Boies Schiller FlexnerWilliam Foege (2016): Former director of the Centers for Disease Control and PreventionFabrizio Bonanni (2016): Former EVP of biotechnology company AmgenStevanato Group (until 2021); XBiotechDaniel Warmenhoven (2016–2017): Former NetApp CEONetApp; Palo Alto Networks (LD until 2020); Aruba Networks; AlteryxRamesh “Sunny” Balwani (unclear dates): COO/boyfriendStory of the Week (MM):CEO proximity to Trump is now a national security threatNvidia CEO Jensen Huang may have been the target of a spy plot through 'Chinese intelligence asset